1. Pink Sheet
  2. >>Pathways & Standards
  3. >>Review Pathways

Accelerated Approval: US FDA Should Explain Why An Ongoing Trial Is Not Required

 
• By Sue Sutter

Having a confirmatory trial underway at the time of approval should be the ‘default expectation’ and the agency should publicly explain when and why it grants exceptions to this rule, experts said at a National Academies meeting on accelerated approval.

Bubbles
To keep skepticism from bubbling up, FDA should explain why it didn't require a trial be underway at the time of approval. • Source: Shutterstock

The US Food and Drug Administration should publicly explain why a confirmatory trial need not be underway at the time a drug receives accelerated approval given the new statutory authority provided by Congress to mandate the timing of such studies, experts said at a National Academies of Sciences, Engineering and Medicine meeting.

Since the Food and Drug Omnibus Reform Act gives the agency clear authority to require that confirmatory studies be underway...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Review Pathways

Gene Therapy Sponsors Seek More US FDA ‘Platform’ Guidance, Offer Master File Idea

 
• By Michael McCaughan

One clear message from a US FDA listening session on leveraging knowledge across cell and gene therapy products is sponsors want more guidance on how the FDA’s new platform therapy pathway will function.

EMA Slashes Average Clock-Stop Extensions By 18% To Speed Up Drug Reviews

 
• By Vibha Sharma

The European Medicines Agency says it is speeding up its review of drug marketing applications through initiatives that restrict requests from companies for additional response time and minimize unnecessary questions from the assessors.

First Cohort Shows Many Routes To US FDA’s Commissioner’s National Priority Voucher

 
• By Sarah Karlin-Smith

Experts raised concerns about the pilot program's larger than expected size and the lack of transparency about the reasons the cohort deserved vouchers over a pool that the FDA said included hundreds of candidates.

US FDA Drug, Biologics Centers Lost Nearly 1,000 Employees In FY 2025 Fourth Quarter

 
• By Derrick Gingery

The hiring and departure data provide more evidence of the extent of the Trump Administration’s efforts to shrink the FDA workforce through cuts and voluntary departures.

More from Pathways & Standards

First Cohort Shows Many Routes To US FDA’s Commissioner’s National Priority Voucher

 
• By Sarah Karlin-Smith

Experts raised concerns about the pilot program's larger than expected size and the lack of transparency about the reasons the cohort deserved vouchers over a pool that the FDA said included hundreds of candidates.

US FDA Drug, Biologics Centers Lost Nearly 1,000 Employees In FY 2025 Fourth Quarter

 
• By Derrick Gingery

The hiring and departure data provide more evidence of the extent of the Trump Administration’s efforts to shrink the FDA workforce through cuts and voluntary departures.

EMD Serono IVF Candidate Among First US FDA Priority Voucher Recipients As Part Of MFN Deal

 
• By Cathy Kelly

A combination of two individual IVF treatments, Pergoveris has the potential to be a lower cost option in the US, one of the qualifications the FDA wants in a National Commissioner's Priority Voucher candidate.